289 related articles for article (PubMed ID: 28661711)
1. Safety of ixazomib for the treatment of multiple myeloma.
Bonnet A; Moreau P
Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Salvini M; Troia R; Giudice D; Pautasso C; Boccadoro M; Larocca A
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):91-99. PubMed ID: 29235380
[TBL] [Abstract][Full Text] [Related]
3. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
4. Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
6. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
7. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
10. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
11. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
12. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Jouni H; Aubry MC; Lacy MQ; Vincent Rajkumar S; Kumar SK; Frye RL; Herrmann J
Am J Hematol; 2017 Feb; 92(2):220-221. PubMed ID: 27859518
[No Abstract] [Full Text] [Related]
13. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
[TBL] [Abstract][Full Text] [Related]
14. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
16. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
[TBL] [Abstract][Full Text] [Related]
18. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
